Loading company…
San Diego-based cancer therapeutics developer working on DNA Damage Response small molecule drugs.
Founded in 2012 and headquartered in San Diego, US, Senhwa Biosciences develops DNA Damage Response therapeutics for cancer, with lead candidates CX-5461 and CX-4945 in Phase I/II clinical trials in several countries. Its Series B round of USD 17.00 mn on December 12, 2013 was led by investors including 5Y Capital and China Investment and Development Company. Taisen Soong is the CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in